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Obesity is associated with increased risk of premature death, morbidity, and mortality
from several cardiovascular diseases (CVDs), including stroke, coronary heart disease
(CHD), myocardial infarction, and congestive heart failure. However, this is not a
straightforward relationship. Although several studies have substantiated that obesity
confers an independent and additive risk of all-cause and cardiovascular death, there
is significant variability in these associations, with some lean individuals developing
diseases and others remaining healthy despite severe obesity, the so-called metabolically
healthy obese. Part of this variability has been attributed to the heterogeneity in both
the distribution of body fat and the intrinsic properties of adipose tissue depots,
including developmental origin, adipogenic and proliferative capacity, glucose and
lipid metabolism, hormonal control, thermogenic ability, and vascularization. In obesity,
these depot-specific differences translate into specific fat distribution patterns, which
are closely associated with differential cardiometabolic risks. The adventitial fat layer,
also known as perivascular adipose tissue (PVAT), is of major importance. Similar
to the visceral adipose tissue, PVAT has a pathophysiological role in CVDs. PVAT
influences vascular homeostasis by releasing numerous vasoactive factors, cytokines,
and adipokines, which can readily target the underlying smooth muscle cell layers,
regulating the vascular tone, distribution of blood flow, as well as angiogenesis,
inflammatory processes, and redox status. In this review, we summarize the current
knowledge and discuss the role of PVAT within the scope of adipose tissue as a
major contributing factor to obesity-associated cardiovascular risk. Relevant clinical
studies documenting the relationship between PVAT dysfunction and CVD with a focus
on potential mechanisms by which PVAT contributes to obesity-related CVDs are
pointed out.
Keywords: perivascular adipose tissue, obesity, vascular function, cardiovascular risk, adipokine
INTRODUCTION
Obesity is a fast-growing problem that is reaching epidemic magnitudes worldwide, affecting
both children and adults (Ogden et al., 2016; Lim et al., 2017). This condition is defined as
a disproportionate body weight for height with excessive fat accumulation that is frequently
accompanied by mild, chronic, systemic inflammation (Gonzalez-Muniesa et al., 2017).
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There is emerging body of scientific, medical, and behavioral data
showing that central deposition of adipose tissue is associated
with elevated risk of morbidity and mortality due to several
cardiovascular complications, including stroke, congestive heart
failure, myocardial infarction, and cardiovascular death, and
this is independent of the association between obesity and the
components of the metabolic syndrome and other cardiovascular
risk factors (Arnlöv et al., 2010; Williams et al., 2015). Previous
support for this understanding was provided by the American
Heart Association in 1998, which has reclassified obesity as a
major, modifiable risk factor for coronary heart disease (CHD)
(Eckel and Krauss, 1998).
Besides being considered the largest energetic reservoir in
the body, white adipose tissue (WAT) has been recognized as a
remarkably complex endocrine organ that produces and secretes
several substances with endocrine, paracrine, and autocrine
functions, acting as a major regulator of systemic energy
homeostasis (Rosen and Spiegelman, 2014). In obesity, adipose
tissue may become dysfunctional and fail to appropriately
expand to store the excess energy. This results in ectopic fat
deposition in other tissues that regulate metabolic homeostasis
(Tchoukalova et al., 2010). WAT expansion has been associated
with numerous local consequences, including inflammation
(Apovian et al., 2008), fibrosis (Henegar et al., 2008), hypoxia
(Jiang et al., 2011), dysregulated adipokine secretion (Jernås et al.,
2006; Skurk et al., 2007), and disrupted mitochondrial function
(Heinonen et al., 2015). The whole-body consequences of WAT
dysfunction include abnormal glucose and lipid metabolism,
insulin resistance, increase in blood pressure, coagulation,
fibrinolysis, inflammation, and endothelial dysfunction, all
of which provide important mechanisms linking obesity to
cardiovascular disease (CVD).
In addition to abdominal adiposity, recent evidence indicates
that perivascular adipose tissue (PVAT) produces and releases
a wide variety of adipokines and other factors that exert a
paracrine influence on the vascular function, not only in veins
and conductance arteries, but also in vessels of smaller caliber,
which are essential in the regulation of blood pressure (Iozzo,
2011; Aghamohammadzadeh et al., 2012; Malinowski et al.,
2013; Szasz et al., 2013). Although PVAT has been considered
an inherent component that provides structural support to the
vessels, now it is clear that this tissue possesses the dynamic
capacity to mobilize near vessels with the potential for cellular
communication and control of vascular function (Sacks and
Fain, 2007; Chatterjee et al., 2009). Local accumulation of
perivascular adipocytes has been consistently associated with
the development of cardiometabolic complications in obesity
(Chang et al., 2013; Lim and Meigs, 2014). In fact, adipose
tissue surrounding the heart has been clinically associated with
coronary artery disease (Cheng et al., 2008; Clément et al.,
2009; Company et al., 2010), which reinforces the evidence that
local adipose tissue accumulation can constitute an important
regulator of cardiovascular function and a mediator of the
development and progression of CVDs. The present review
provides a comprehensive overview on the role of PVAT within
the scope of adipose tissue as a major contributing factor to
obesity-associated cardiovascular risk. We will also highlight the
relevant clinical studies documenting the relationship between
PVAT dysfunction and CVD and the potential mechanisms
by which PVAT contributes to obesity-related cardiovascular
complications.
OBESITY AND CARDIOVASCULAR RISK
Over the past decades, an explosive increase in overweight and
obesity prevalence has taken place in most of the high-income
countries (Vandevijvere et al., 2015). Several recent reviews
have also shown significant increases in the prevalence of these
conditions in low- and middle-income countries, affecting both
men and women, adults and children (Gupta et al., 2012; Popkin
and Slining, 2013; Sayon-Orea et al., 2013; Yatsuya et al., 2014).
Although there are great variations in the prevalence and trends
of overweight and obesity among different regions, the numbers
have been projected to further increase in coming years (Gupta
et al., 2012; Popkin and Slining, 2013; Sayon-Orea et al., 2013;
Yatsuya et al., 2014; Poobalan and Aucott, 2016). The percentage
of adults with a body mass index (BMI) ≥25 kg/m2 between
1980 and 2013 increased in men and women from 28.8% (95%
UI: 28.4–29.3) to 36.9% (36.3–37.4), and from 29.8 to 38%,
respectively. Among children and adolescents, in 2013, 23.8%
(22.9–24.7) of boys and 22.6% (21.7–23.6) of girls were either
overweight or obese in developed countries (Ng et al., 2014).
The prevalence rate in developing countries elevated from 8.1%
(7.7–8.6) to 12.9% (12.3–13.5) for boys and from 8.4% (8.1–
8.8) to 13.4% (13.0–13.9) in girls, in 2013. The World Health
Organization (WHO) estimated that more than 2.1 billion adults
were overweight or obese globally in 2014. By 2030, estimations
predict that 57.8% of the adult population will have a BMI of 25
kg/m2 or higher (Kelly et al., 2008; Finkelstein et al., 2012). As
such, the adverse health consequences of obesity, particularly the
burden of CVDs are expected to increase in coming years.
In adults, obesity generally presents as an excess of body
weight and adipose tissue, which is clinically assessed by the
BMI, calculated by the weight in kilograms divided by the height
in square meters (Garrow and Webster, 1985). The idea that
BMI is associated with higher all-cause morbidity/mortality risk
is supported by a wealth of epidemiological and clinical data
(Borrell and Samuel, 2014; Yang et al., 2016; Kong et al., 2017).
However, a recent comprehensive estimation, resulting from
a systematic review on the association of all-cause mortality
in adults with BMI categories used in the United States and
internationally, demonstrated that while grades 2 and 3 obesity
are both associated with significantly higher all-cause mortality,
overweight (defined as a BMI of 25 – <30) is associated with
significantly lower overall mortality relative to the normal weight
category. Furthermore, the authors did not find significant excess
mortality associated with grade 1 obesity (BMI of 30 – <35)
(Flegal et al., 2013), suggesting that cardiovascular risk and
mortality are not simply associated with the amount of adipose
tissue.
Adipose tissue is dispersed throughout the body in discrete
depots ranging from 5 to 60% of total body weight (Cinti, 2001).
More than 80% of the tissue is found subcutaneously, mainly
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in the abdominal, gluteal and femoral areas. Visceral adipose
tissue and smaller depots close to organs represent the remaining
10–20% of total body fat in men and 5–10% in women (Lee
et al., 2013). It has become increasingly evident that the regional
body fat distribution, the size of each depot, the depot-related
differences in adipose tissue function, and the balance between
them are important for the individual cardiometabolic risk. For
example, a peripheral adiposity in upper and lower extremities
is favorable while the truncal adipose tissue deposition, which
includes subcutaneous fat in thoracic and abdominal region
and the fat in intrathoracic and intraabdominal regions, is
detrimental and associated with increased mortality (Garg,
2004; McLaughlin et al., 2011). Moreover, for any given BMI-
value, there is significant variability with some lean individuals
developing disease and others exhibiting a better metabolic
profile than expected for their adiposity profile (Samocha-
Bonet et al., 2012). Lapidus et al. in 1980s, reported a stronger
association of waist-to-hip circumference ratio, which reflects
abdominal fat, with a 12-year incidence of myocardial infarction,
angina pectoris, stroke, and death, when compared to other
anthropometric measures (Lapidus et al., 1984). Subsequently,
many clinical studies have established the superior capability of
waist-to-hip ratio measure to predict CVD risk when compared
to BMI.
The large-scale randomized factorial clinical trial study
ADVANCE (Action in Diabetes and Vascular disease: Preterax
and Diamicron-MR Controlled Evaluation) examined the
relative importance of different adiposity markers in predicting
CVD risk in a population of individuals with type 2 diabetes
(Czernichow et al., 2011). After 9.1 years of follow up,
investigators reported that waist-to-hip ratio is the best predictor
of cardiovascular events and mortality in patients with type-
2-diabetes while the BMI is the worst. The INTERHEART
study, a large multiethnic case-control study of acute myocardial
infarction, also evidenced a greater contribution for waist-to-hip
ratios accounting for most of the risk of myocardial infarction
when compared to BMI, in both sexes and at all ages (Yusuf et al.,
2004). A meta-analysis using data pooled from 15 prospective
studies that included more than 258,000 subjects reported a
progressive increase in cardiovascular risk accompanying the
increase in waist circumference and waist-to-hip ratios (de
Koning et al., 2007). Specifically, every 1 cm of increase in waist
circumference was associated with a 2% increased relative risk
of cardiovascular event and a 0.01 increase in waist-to-hip ratio
was associated with a 5% increase in risk of future CVD for both
men and women. The Nurses’ Health Study, one of the largest
and longest studies to date that measured abdominal obesity,
confirmed these findings using the waist circumference measure
(Zhang et al., 2008). The investigators reported that during 16
years of follow-up in US women, elevated waist circumference
was associated with significantly increased CVD mortality even
among normal-weight women.
As obesity is strongly linked to comorbid conditions,
including type 2 diabetes, hypertension, hypercholesterolemia,
hypertriglyceridemia, and non-alcoholic fatty liver disease, these
risk factors have been considered important intermediate steps
in the causal relationship between obesity and CVD risk. From
this perspective, there has been considerable debate about
whether the adjustment for these risk factors in statistical
models is necessary for the true absolute risk predicting CVD
risk or whether such adjustments, rather than controlling for,
may increase the overall risk of bias. In fact, the increased
cardiovascular risk attributed to weight gain persists even after
adjustment for the frequently observed co-existing risk factors.
In 1983, a 26-year follow-up of participants in the Framingham
Heart Study reported that this risk was particularly apparent
for heart failure, but it was also identified with CHD, stroke,
and death from CVD. Kenchaiah and colleagues also provided
unequivocal evidence in 2002, using updated Framingham data.
According to authors, approximately 11% of heart failure cases
among men and 14% among women are attributable to obesity
alone, suggesting that efforts to promote optimal body weight
may reduce the risk of heart failure (Kenchaiah et al., 2002).
A careful review of these studies further supports the idea that
composition of adipose tissue is important for cardiovascular
risk stratification and characterizes visceral adipose tissue as
an incomparable pathogenic depot that confers risk beyond its
contribution to overall adiposity. These constraints that govern
the outcomes of obesity are described in a recent review by
Mahmood et al. (2014) and emphasizes the importance of adipose
tissue depots as potential components in assessing and predicting
cardiometabolic risk.
SYSTEMIC ADIPOSE TISSUE
DYSFUNCTION AND VASCULAR
FUNCTION IN OBESITY
The WAT is no longer considered to be only a passive tissue
for the storage of excess energy in the form of fat. There is
now compelling evidence that this tissue acts as an endocrine
organ that produces and releases biologically active compounds
that regulate metabolic and cardiovascular homeostasis and
undergoes pathological expansion during obesity (Waki and
Tontonoz, 2007; Coelho et al., 2013). In addition to the better-
known WAT, mammals also exhibit brown adipose tissue
(BAT). Functional BAT in adult humans is localized to areas
close to the clavicular, periaortic, cervical, and suprarenal
regions (Cypess et al., 2009). BAT is an energy-expending
organ that produces heat, and it is essential for adaptive
thermogenesis. Adipocytes from BAT possess large numbers of
mitochondria that contain a unique protein called uncoupling
protein 1 (UCP1), which is a proton channel within the inner
mitochondrial membrane involved in the dissipation of the
proton motive force that is normally used to drive the synthesis
of cellular ATP. Consequently, the energy in the mitochondrial
electrochemical gradient is released in the form of heat (Cannon
and Nedergaard, 2004). Indeed, evidence from clinical and
experimental studies indicate that BAT activation increases
thermogenesis (Lidell and Enerback, 2010). Recent reports have
also unequivocally demonstrated that BAT exerts significant
impact on whole-body energy homeostasis and that its activity
profoundly influences body weight (Fruhbeck et al., 2009). In
fact, overweight and obesity have been associated with lower BAT
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activity (Vijgen et al., 2011), which is increased after weight loss
(Vijgen et al., 2012). Together with data obtained from rodent
models (Vegiopoulos et al., 2010; Seale et al., 2011; Kiefer et al.,
2012), these reports have drawn attention to BAT as an attractive
target for the treatment of obesity and associated metabolic
diseases. Hence, potent or permanent interventions targeting
on induction of brown phenotype in adipose tissue depots will
facilitate long term studies to investigate their precise role in
driving metabolic diseases and to determine their potential to
attenuate cardiovascular risk. However, it is discernible that such
a critical approach will require layers of specificity, beyond the
targeting of individual components of WAT, considering the
possibility that factors involved in browning of specific adipose
tissue depots may not share similar regulatory network.
A highly relevant factor for the understanding of the
cardiovascular impact of increased adipose tissue mass is
the recognition that adipocytes are endocrine and paracrine
determinants of vascular function. The great question that arises
from these observations is how excessive accumulation of adipose
tissue could lead to the development of such dysfunction even
at a distance. The answer to this question is provided by
the evidence that adipose tissue is involved in the production
of various proteins, collectively called adipokines (including
chemokines, cytokines, and hormones) (Kershaw and Flier,
2004), which are secreted into the circulatory system and act
in several physiological processes, including energy balance,
immune responses, blood pressure, vascular homeostasis and
angiogenesis, glucose and lipid metabolism, and even insulin
sensitivity (Prins, 2002), all of which may contribute to the
elevated cardiovascular risk associated with obesity (Weyer et al.,
2000; Wang et al., 2005). The positive energy balance induces an
expansion and remodeling of the adipose tissue that is initially
driven by adipocyte hyperplasia mediated by the recruitment and
proliferation of adipogenic progenitors followed by an increase
in adipocyte hypertrophy (Hausman et al., 2001; Spalding et al.,
2008), which lead to dysregulated secretion of adipokines and
increased release of free fatty acids (Figure 1).
Although the altered secretory function of adipose tissue
is consistent with the idea that chronic obesity-related low-
grade inflammation in adipose tissue is involved in the
metabolic complications of obesity, it is important to consider
that adipocytes in adipose tissue are not the only culprit.
Regardless of the mechanisms of adipose tissue expansion,
positive energy balance eventually leads to necrotic and/or
apoptotic cell death and this is paralleled by quantitative
and qualitative changes in the cellular composition and the
phenotype of individual cells within adipose tissue (Weisberg
et al., 2003). For example, adipose tissue from obese individuals
is infiltrated by numerous activated macrophages, leading to
increases in both absolute macrophage number and the relative
level of macrophage-to-adipocyte ratio. In addition to this
quantitative change, the macrophage phenotype is also altered
by the obesity state. Macrophages that accumulate in adipose
tissue of obese organisms tend to express genes associated
with increased production of pro-inflammatory cytokines,
express inducible nitric oxide synthase (iNOS), and produce
high levels of reactive oxygen species (ROS), and nitrogen
intermediates (Lumeng et al., 2007). Thus, it has become evident
that interactions between the different cell types from enlarged
and inflamed adipose tissue contribute to its overall impact on
obesity-related disorders. In fact, some evidence exists that the
release of some adipokines is even higher from the cells of the
stroma-vascular fraction than from adipocytes (Chavey et al.,
2009; Hamaguchi et al., 2012).
Adipose tissue dysfunction may also promote a state of
systemic endothelial cell activation through the endocrine actions
of inflammatory adipokines (Skurk et al., 2007; Dulloo et al.,
2010). The impact of these adipokines on vascular function
is not limited to the momentary regulation of the release of
endothelium-derived vasoactive factors or regulation of vascular
smooth muscle tone. Some adipokines may also profoundly
affect local growth, migration, and inflammatory processes (Miao
and Li, 2012). Obviously, these variety of products secreted
by the adipose tissue, without even reporting the entirety
of released adipokines, have provided promising possibilities
for identifying novel biomarkers associated with obesity and
the cardiovascular complications associated with this condition
(Bagi et al., 2012; Barton et al., 2012). Although these studies
set several adipokines into their functional context enhancing
our current knowledge of the endocrine function of the
adipose tissue, the identified proteins must be further validated
regarding their expression, secretion and function. Translation
of protein profiling results into clinical use will contribute
to validate novel adipokines potentially representing a link
between obesity and human disease. In this regard, studies must
move from characterizing protein abundances to elaboration of
their functional effects within cellular networks. However, since
human genetic variability is estimated to contribute variations in
the capacity of different adipose tissue depots to store and release
fatty acids and to produce adipokines (White and Tchoukalova,
2014), and many of the direct genetic achievements are still being
investigated for their causal impact on phenotypic outcomes, it
is prudent to interpret both positive and negative results with
caution. Integrated approaches including the analysis of multiple
scientific fields will certainly enhance the understanding of this
new physiological concept of interorgan crosstalk in the context
of obesity.
PERIVASCULAR ADIPOSE TISSUE
EFFECTS ON VASCULAR FUNCTION
Besides the endocrine role of adipose tissue, mediated by
adipokines, a major emerging concept indicates that ectopic fat
depots surrounding the heart and almost all systemic blood
vessels, can also directly affect the cardiovascular function
(Chang et al., 2013). These include: the PVAT, that is, the fat
immediately adjacent to the adventitia of almost all arteries; the
epicardial adipose tissue, which refers to the fat depot laying
on the surface of the myocardium surrounding the coronary
arteries; and the pericardial adipose tissue, the fat depot located
between the visceral and parietal pericardium (Iozzo, 2011).
Notably, this anatomical proximity of PVAT has an enormous
influence on the cardiovascular system and highly vascularized
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FIGURE 1 | Mechanisms by which systemic adipose tissue dysfunction could lead to the development of vascular dysfunction in obesity. Adipose tissue produces
various chemokines, cytokines and hormones, which are secreted into the circulatory system and act in several physiological processes, including energy balance,
immune responses, blood pressure, vascular homeostasis and angiogenesis, glucose and lipid metabolism. Expansion of the adipose tissue leads to necrotic and/or
apoptotic cell death and this is paralleled by infiltration of activated macrophages, increased production of pro-inflammatory adipokines and reactive oxygen species,
promoting a state of systemic endothelial cell activation and vascular dysfunction, all of which may contribute to the elevated cardiovascular risk associated with
obesity.
organs (e.g., the kidney). In fact, over the past years, clinical
and experimental evidence accumulated recognizing that PVAT
not only stores triacylglycerols/triglycerides and free fatty acids,
participating in energy metabolism, but also secretes a wide
variety of biologically active molecules, including adipokines,
such as leptin, adiponectin, chemerin, visfatin, resistin, tumor
necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-
18 (IL-8), monocyte chemoattractant protein-1 (MCP-1), and
plasminogen activator inhibitor 1 (PAI-1), which modulate
vascular tone (Maenhaut and Van de Voorde, 2011), smooth
muscle cells migration and proliferation (Miao and Li, 2012),
neointimal hyperplasia and formation (Takaoka et al., 2010;
Schroeter et al., 2013), inflammatory responses and oxidative
stress (Salgado-Somoza et al., 2010). Most of these properties
converge on endocrine-related effects, but also on a direct,
paracrine influence in CVD, not only on large arteries and veins,
but also in small and resistance vessels, and skeletal muscle
microvessels, considered to be of greatest importance in blood
pressure regulation, as has been reviewed elsewhere (Szasz et al.,
2013; Xia and Li, 2017).
The structural and physiological characteristics of
PVAT vary according to its location. In the mesenteric
arteries, PVAT resembles WAT, with less differentiated
adipocytes, poor vascularization, a specific profile of cytokines
production/secretion, and contains infiltrates of macrophages,
fibroblasts and cells of the immune system (Guzik et al., 2013).
On the other hand, recent studies have demonstrated that PVAT
of the thoracic aorta exhibits features that resemble BAT rather
thanWAT (Fitzgibbons et al., 2011; Chang et al., 2012), including
expression of genes highly or solely expressed in the BAT, the
presence of multilocular adipocytes and high abundance of
mitochondria. Like BAT, PVAT is activated by cold and generates
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heat. Interestingly, the cold-induced activation of thermogenesis
in PVAT is accompanied by attenuation of the atherosclerotic
process in apolipoprotein E deficient mice (ApoE−/−), whereas
such protection is lost in mice where PVAT is absent (Chang
et al., 2012), indicating that the thermogenic properties of PVAT
also mediate its vascular protective effects.
Consistent with the findings that thoracic aorta PVAT shares
common characteristics with BAT, our group has recently
demonstrated a potential role of mitochondria in periaortic
adipose tissue as a source of mediators that could be involved
in the modulation of vascular contraction along with the
PVAT-derived relaxing factors (Costa et al., 2016). These are
all exciting developments that have the potential to provide
insight into new aspects of the specific nature and function
of different adipose tissue depots while also places PVAT as
a promising component of investigation regarding brown fat
and its potential beneficial effects, including those on the
vasculature. Further work is required to resolve interesting
questions raised by these findings: are the precursor components
of PVAT adipocytes distinct from those of white or BAT?
Although the morphology and mRNA/protein profile of PVAT
is evocative of classic BAT, is this tissue a true BAT? Recent
studies have illustrated a remarkable possibility that the origin
of PVAT adipocytes may so far be distinct from either white or
brown adipocytes. Using a vascular smooth muscle cell (VSMC)-
specific nuclear receptor activated by peroxisome proliferator-γ
(PPARγ) deletion, Chang group generated mice completely
devoid of PVAT in the aortic and mesenteric regions while
both interscapular BAT and gonadal/inguinal/subcutaneous
WAT remained intact, indicating that BAT, WAT, and PVAT
have different origins (Chang et al., 2012). In this regard,
the previous observation of Chatterjee’s group demonstrated
that in vitro differentiated human coronary artery perivascular
adipocytes exhibit a distinct state of adipogenic differentiation
and adipokine secretion when compared with adipocytes from
subcutaneous or visceral adipose depots (Chatterjee et al., 2009),
suggesting that PVAT exhibit a unique gene expression profile
that underlies its role in vascular function. Although these well-
established strategies provide extremely promising prospects,
an unresolved question is the relative contribution of different
brown and brown-like fat depots to metabolic and CVD in
humans. Whether PVAT thermogenesis can be targeted for
therapeutic purposes needs to be determined. It also seems
clear that understanding the differences between PVAT depots,
specifically, the functional analysis of bioenergetics in this tissue
and its impact on systemic metabolism is a very promising
approach in the context of metabolism and the etiology of the
spectrum of cardiometabolic disorders.
The concept that PVAT influences vascular function,
particularly contractile responses, dates from at least as early as
the 1990s, when Soltis and Cassis described that PVAT retained
and impaired the diffusion of pharmacological agents, justifying
a reduction in the contractile response observed in vessels
with this tissue (Soltis and Cassis, 1991). However, subsequent
studies using several agonists of low retention in adipocytes also
demonstrated such a decrease (Gollasch and Dubrovska, 2004).
Löhn and his colleagues found that the vascular responses to
angiotensin II (Ang II), serotonin (5-HT), and phenylephrine
(PE) are reduced in intact aortas with PVAT, suggesting that
periaortic adipose tissue regulates vascular tone by the release
of transferable adventitia-derived relaxing factors (ADRF), now
defined as PVAT-derived relaxant factors (PVRF) (Lohn et al.,
2002). The anti-contractile effect of PVRFs under physiological
conditions has been described in several species and is mediated
by different mechanisms depending on the vascular bed.
Convincing evidence has demonstrated that VSMC potassium
(K+) channels play a critical role in mediating the relaxation
responses to PVRFs. The study of Löhn showed that the anti-
contractile effect of periadventitial fat was reduced by inhibition
of ATP-dependent K+ channels and by the tyrosine kinase
inhibitor genistein (Lohn et al., 2002). Following these findings,
subsequent studies demonstrated that PVAT-derived transferable
factors produce vasorelaxation by opening of voltage-dependent
K+ (Kv) channels (Dubrovska et al., 2004; Verlohren et al.,
2004; Gao et al., 2005; Fesus et al., 2007). Schleifenbaum’s group
further explored the involvement of the Kv-subfamily on PVRFs
actions. The authors demonstrated that the voltage-activated
family of K+ channels KCNQ (Kv7), which are not targeted by
endothelium-derived relaxing factors (EDRF), play significant
role in the vasorelaxation induced by PVRFs, which is at least
in part mediated or modulated by hydrogen sulfide (H2S).
Although the KCNQ channel subtype involved in the PVRF
effects has not been identified so far and clear evidence for
direct activation of KCNQ channels by PVRF is still missing, the
opening of these channels by pharmacological agents restores
the diminished anti-contractile effects of perivascular fat in
spontaneously hypertensive rats, thus suggesting its pivotal role
in perivascular regulation of vascular tone (Schleifenbaum et al.,
2010).
Although we are unable to cover the topic in detail in this
manuscript, it is important to note that many other mechanisms
involved in PVRF-induced anti-contractile effects have been
described. Lu and collaborators, by using inferior vena cava
rings in the absence and presence of PVAT and endothelium,
found that endothelium removal abolishes PVAT anti-contractile
response. The same group of researchers has suggested that
PVAT releases Ang 1–7, which, by acting on receptors in the
endothelium, leads to nitric oxide (NO) release and activation
of Kv channels with subsequent vascular relaxation (Lu et al.,
2011). PVRF may also act through endothelium-independent
mechanisms involving hydrogen peroxide (H2O2) production
and subsequent activation of guanylyl cyclase (sGC) (Gao et al.,
2007).
In addition to the vasodilator effects, there is also considerable
evidence of contractile function mediated by PVAT. Soltis and
Cassis reported the critical role of adipocyte-derived Ang II in
PVAT-mediated potentiation of electrical stimulation-induced
contraction in rat mesenteric arteries (Soltis and Cassis, 1991).
This effect was subsequently shown in vivo systemically in rat
mesenteric PVAT (Lu et al., 2010). Gao et al. also reported that
PVAT enhances the contractile response of mesenteric arteries to
perivascular nerve stimulation through superoxide anion (O−2 )
production (Gao et al., 2006). The study of Payne documented
that PVAT impairs coronary endothelial function in response to
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bradykinin both in vitro and in vivo, implicating local adipose
tissue in the initiation and pathogenesis of coronary vascular
disease (Payne et al., 2008). In particular, the authors documented
that adipose tissue-derived factors diminish endothelial NO
production through the direct inhibition of the enzyme
NOS. Following these findings, the authors demonstrated that
periadventitial adipose tissue-derived factors impair coronary
endothelial NO production via a PKC-β-dependent, site-specific
phosphorylation of endothelial NOS (eNOS) at Thr495 (Payne
et al., 2009). Some adipose tissue-derived factors, such as leptin
(Knudson et al., 2005), resistin (Dick et al., 2006), and TNF-α
(Picchi et al., 2006), secreted under conditions of inflammation,
can also attenuate vasodilatation, and these factors are produced
by PVAT.
In the last years, several studies identified additional
components involved in the contractile effects of PVAT, which
have been reported especially in the context of obesity and
CVD. One example of this is the study of Meyer’s group, which
demonstrated that PVAT controls arterial smooth muscle tone
by releasing an “adipocyte-derived contracting factor” (ADCF)
formed by cyclooxygenase (COX), whichmediates the contractile
effects of PVAT in obesity (Meyer et al., 2013). Another powerful
example is the work of Watts et al. illuminating a potential role
for the adipokine chemerin as an endogenous mediator that is
responsible for vasoconstriction in obesity (Watts et al., 2013).
In line with these observations, our group demonstrated that
incubation of isolated vessels with chemerin for 24 h increases
arterial sensitivity to endothelin-1 (Lobato et al., 2012). Thus, it is
clear that PVAT is a complex, active organ with several functions
beyond mechanical protection for the underlying vasculature
and the current literature provides substantial evidence that
this tissue produces many putative vasoactive factors that may
influence vascular function and obesity-related vascular injury.
However, most of these characterization studies have been carried
out on vessel rings isolated from animal models, in the presence
or absence of the PVAT layer. This poses an important and
unresolved question regarding how much of these results can
be translated in vivo, especially concerning human physiology.
A thoughtful consideration of the implications of manipulating
PVAT function to treat chronic vascular diseases is therefore
warranted.
PERIVASCULAR ADIPOSE TISSUE
DYSFUNCTION AS A MAJOR
CONTRIBUTING FACTOR TO
OBESITY-ASSOCIATED VASCULAR
DYSFUNCTION
As the understanding of the molecular mechanisms that underlie
the connections between PVAT and vascular function progress,
the ultimate goal is to establish the integrated role of this
vascular component for obesity-related vascular dysfunction.
Like observed with the total adipose tissue, PVAT mass is
increased throughout the vasculature in both animal models and
humans with obesity (Greenstein et al., 2009; Marchesi et al.,
2009; Ketonen et al., 2010; Lehman et al., 2010). Considering
that the anti-contractile influence of PVAT is directly dependent
on its volume (Verlohren et al., 2004; Gao et al., 2006), it
would be discernible that such an increase would be associated
with enhancement of PVAT anti-contractile effects. However,
available support for our understanding of the connection
between PVAT and vascular dysfunction in obesity comes from
the findings that obesity is associated with structural and
functional changes in PVAT, leading to an imbalance in favor
of vasoconstrictor and pro-inflammatory substances, as well as
changes in the signaling pathways in the vessel and that this
condition interferes with vascular function (Figure 2). Numerous
studies have since validated this postulate (reviewed in Xia
and Li, 2017). In line with this observation, Gao et al. (2005)
demonstrated that increased adiposity causes an alteration in the
modulatory function of PVAT on vascular relaxation response.
New Zealand Obese (NZO) mice, which present most symptoms
of the metabolic syndrome and a greater amount of PVAT, also
show a reduction in the anti-contractile effect of PVAT (Fesus
et al., 2007). Higher periaortic fat mass in rats treated for 6
months with high fat diet (HFD) lead to reduced endothelium-
dependent relaxation due to downregulation of AMP-activated
protein kinase (AMPK) and eNOS in the aorta with a concurrent
upregulation of the mTOR ripamycin target, which negatively
regulates the AMPK-eNOS pathway (Ma et al., 2010). Another
important milestone toward our basic understanding of the
relationship between PVAT dysfunction and obesity-associated
vascular dysfunction was the demonstration of changes in
the proteomic profile of 186 proteins in PVAT of coronary
arteries, which correlate with increased contractile effect and the
activation of calcium (Ca2+)-dependent signaling pathways in
VSMCs from Ossabaw pigs (Owen et al., 2013).
These considerations aside, the diverse aspects of PVAT
influence on vascular dysfunction in obesity could be also framed
by examining its high relationship with oxidative stress. ROS,
such as O−2 and H2O2, play important roles in the modulation
of vascular function by the PVAT. H2O2 is a vasoactive
substance that induces both contractile and relaxing responses
by different mechanisms depending on its concentration, the
type and contraction state of the vessel, and the animal species.
H2O2-induced relaxation may be endothelium dependent as
a result of increased NO release secondary to K+ channel
activation. In addition, H2O2 induces endothelium-independent
relaxation through the direct opening of K+ channels in VSMC,
by the oxidation of its cysteine residues, as well as by the
direct activation of the sGC enzyme (Ardanaz and Pagano,
2006). The contractile effect mediated by H2O2 occurs due to
the direct activation of the enzyme COX and an increase of
intracellular Ca2+. Evidence indicates that ROS accumulation
activates contraction pathways related to MAPKs, with increased
ERK 1/2 phosphorylation (Peters et al., 2000). In addition, H2O2
activates the Rho kinase pathway, favoring vascular contraction
(Ardanaz and Pagano, 2006). In fact, the Rho kinase pathway
is important not only in the contraction of VSMC, but also in
increased proliferation and cell migration, which has attracted
much attention in relation to its role in the pathogenesis of CVDs
(Loirand et al., 2006). Considering that O−2 induces vascular
contraction while H2O2 has dual effects, the final result of the
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FIGURE 2 | Perivascular adipose tissue dysfunction and obesity-associated vascular dysfunction. Perivascular adipose tissue (PVAT) secretes a wide variety of
biologically active molecules, including the adipokines, which modulate vascular tone, smooth muscle cells migration and proliferation, neointimal hyperplasia,
inflammatory responses, and oxidative stress. Obesity is associated with structural and functional changes in PVAT, leading to an imbalance in favor of vasoconstrictor
and pro-inflammatory substances, adipocytes hypertrophy as well as changes in insulin signaling pathways. SMC, smooth muscle cell; ROS, reactive oxygen species;
NO, nitric oxide.
action of these ROS will depend on the relative balance between
the production and the release of these factors by the PVAT.
Ketonen et al. demonstrated in C57BL/6J mice fed a HFD that
the reduction in endothelium-dependent relaxation occurs due
to oxidative stress in PVAT, characterized by an increase in O−2
and H2O2 production (Ketonen et al., 2010).
The NAD(P)H oxidase, which is the major source of O−2 in
the vasculature, is expressed in PVAT of rat mesenteric arteries
and contributes to increased contractile response to perivascular
nerve stimulation (Gao et al., 2006). Indeed, the expression of
p67phox subunit of the NAD(P)H oxidase complex is increased
in periaortic adipose tissue from short-term fed HFD obese mice
(60% cal from fat) and this is accompanied by enhancement
of both O−2 and H2O2 levels (Ketonen et al., 2010). Increased
NAD(P)H oxidase activity and O−2 production associated with
decreased expression of total SOD activity and extracellular
superoxide dismutase (ecSOD) were described in the PVAT of
these animals. The changes were accompanied by a reduction in
eNOS expression and NO production in the PVAT (Gil-Ortega
et al., 2014). Similarly, in NZO mice, increased O−2 formation
and reduced SOD expression in PVAT contribute to vascular
dysfunction by reducing the anti-contractile effect of this tissue
(Marchesi et al., 2009). Gil-Ortega et al. reported that long-
term HFD induces substantial reduction in ec-SOD expression
and total SOD activity, an increase of NOX activity and O−2
release from the mesenteric PVAT, suggesting that the imbalance
between antioxidant and pro-oxidant mechanisms in PVAT
might contribute to vascular oxidative stress, thus aggravating
endothelial dysfunction (Gil-Ortega et al., 2014). Marchesi et al.
have also shown that the loss of PVAT anti-contractile properties
in NZO mice might be associated with increase in both O−2 and
NAD(P)H oxidase activity (Marchesi et al., 2009). Uncoupling
of eNOS in PVAT, which contributes not only to increase ROS
formation but also to decrease NO bioavailability, was also
recently described as a novel mechanism underlying the vascular
dysfunction in diet-induced obesity (Xia et al., 2016).
The mitochondrial electron transport chain (mETC), a
significant source of ROS, has also been pointed as an integral
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component implicated in the physiological regulation of vascular
function by PVAT. We recently showed that O−2 production
from the mETC is increased in PVAT during norepinephrine
(NE)-induced aortic muscle contraction. O−2 is subsequently
dismutated to H2O2 by manganese SOD (Mn-SOD), which,
in turn, modulates VSMC contraction (Costa et al., 2016).
Following these findings, we next provided unequivocal evidence
linking mitochondria to PVAT-associated oxidative stress and
the subsequent loss of the PVAT anti-contractile effects observed
in experimental obesity (da Costa et al., 2017). Under these
conditions, the increase in PVAT-mediated ROS generation
becomes an important sign of increased vascular contraction. As
PVAT has a similar phenotype to BAT, including the expression
of UCP-1, which is necessary for non-shivering thermogenesis,
as discussed above, and considering that local energy metabolism
induced by changes in temperature affects vascular function
and atherogenesis (Brown et al., 2014), it can be proposed that
increased energy production in PVAT under obesity condition
also affects vessel biology favoring the development of CVD.
Structural and functional modifications of PVAT in obesity
can also induce vascular remodeling. Periaortic adipocytes
significantly increase the growth rate of aortic smooth muscle
cells from aged and obese Wistar Kyoto rats supplemented with
HFD. This effect is abolished in the presence of proteinase
K, but is maintained in the presence of filtered proteins with
a molecular mass less than 100 kDa, indicating that PVAT
releases soluble proteins that stimulate growth of VSMCs, which
can further aggravate aging- and obesity-associated vascular
diseases (Barandier et al., 2005). Finally, the paracrine actions
of factors produced and released by PVAT can also change
vascular insulin sensitivity (Meijer et al., 2013). Although the
prospective association between PVAT dysfunction and diabetes
has not been demonstrated so far, this possibility has been
previously postulated by Yudkin et al. and remarkably illustrated
by several subsequent studies (Yudkin et al., 2005). Meijer’s
group showed that local depots of PVAT, which surround
resistance arteries in the muscle microcirculation, controls
vascular responses to insulin through adiponectin secretion
and subsequent activation of AMPK signaling (Meijer et al.,
2013). The expression of adiponectin is significantly lower
in the epicardial adipose tissue isolated from patients with
CAD (Iacobellis et al., 2005). In humans, PVAT accumulation
around the brachial artery was negatively correlated with
insulin sensitivity and the post-ischaemic increase in blood
flow. The association was independent of the presence of other
cardiovascular risk factors, including age, sex, liver fat, BMI,
and visceral adipose tissue (Rittig et al., 2008). Additionally,
PVAT from obese mice inhibits insulin-induced vasodilatation,
which can be restored by inhibition of the inflammatory kinase
Jun NH (2)-terminal kinase (JNK) (Meijer et al., 2013). JNK
may directly induce insulin resistance by a mechanism that
involves phosphorylation of the insulin receptor substrate (IRS)
1, blocking the transduction signal produced by the insulin
receptor (Sabio et al., 2008). Studies in humans and animal
models have demonstrated an important upstream role of this
protein in integrating inflammatory and metabolic function that
were recently reviewed elsewhere (Hotamisligil, 2017).
These findings, in addition to the observations that local
accumulation of adipose tissue is consistently related to decreased
flow-mediated vasodilation (Albu et al., 2005), fasting insulin
levels and insulin resistance in humans (Rittig et al., 2008),
support the involvement PVAT-derived factors as paracrine,
rather than endocrine mediators of both microvascular
dysfunction and insulin resistance in obesity. There is also
tremendous redundancy in these pathways that support the view
that the association between PVAT and cardiometabolic risk
factors might not simply be the consequence of overall adiposity,
but potentially constitutes an additional risk factor. Considering
that hyperglycemia and hyperinsulinemia can also directly
impair vascular function and consequently glucose disposal, it is
also possible to suggest a vicious cycle of PVAT dysfunction that
contributes to and is exacerbated by the impairment in insulin
homeostasis.
INFLAMMATION IN PERIVASCULAR
ADIPOSE TISSUE: THE LINK BETWEEN
OBESITY AND CARDIOVASCULAR
DISEASE?
In the last decades obesity has been associated with a moderate
degree of inflammation in adipose tissue, a condition that
results from chronic activation of the innate immune system.
This type of inflammation, called metaflammation or metabolic
inflammation is free of pathogens and orchestrated by metabolic
cells in response to excess nutrients and energy (Hotamisligil,
2017). Initial support for this understanding came from the
following observations: macrophages-derived TNF-α induces
insulin resistance in adipocytes (Pekala et al., 1983); adipose
tissue from obese individuals displays increased expression
of inflammatory mediators (Hotamisligil et al., 1993; Uysal
et al., 1997); and inflammation promotes disturbances in
glucose metabolism. It is relevant to emphasize here the first
demonstrations that macrophage infiltration occurs into the
adipose tissue in obesity (Weisberg et al., 2003; Xu et al.,
2003). These findings were the basis for elucidating the
involvement of adipose tissue macrophages as direct modulators
of metabolism, and led to the observations that the increased
free fatty acids exposure in obesity promotes the polarization
of macrophages resident in the adipose tissue toward a pro-
inflammatory (M1-polarized) phenotype which can activate
inflammatory pathways and impair insulin signaling (Hevener
et al., 2007; Lumeng et al., 2007; Nguyen et al., 2007).
The molecular mechanisms underlying these events include
epigenomic alterations that determine macrophage sensitivity
to metabolically driven inflammatory (metaflammatory) signals
(Fan et al., 2016), and additional macrophage-secreted products,
including the potent and pleiotropic immune mediator TNF-
α, which attenuates insulin signaling in adipocytes (Li et al.,
2016). Many other immune cells including dendritic cells,
mast cells, eosinophils, and lymphoid cells also contribute to
metabolic tissue homeostasis and to the control of glucose
metabolism. Regarding the initiation of metaflammation, an
emerging concept is that adipocyte hypertrophy causes local
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hypoxia, which, in turn, causes infiltration of macrophages and
other immune cells (CD4+ and CD8+ T cells, natural killer T
cells, and mast cells) in visceral adipose tissue (Roemeling-van
Rhijn et al., 2013). This increase in cells of the immune system
along with the proinflammatory cytokines in adipocytes may
negatively regulate PPARγ activity, which is essential for both
adipogenesis andmaintenance of the tissue gene expression (Guri
et al., 2008).
Intermittent inflammatory processes have also been observed
in PVAT. These include increased migration of immune cells,
altered production of pro- and anti-inflammatory cytokines,
adipokines, and lipid mediators, as well as signaling through
a plethora of immune receptors and intracellular signaling
molecules. Importantly, this entire cascade and mediators
have now provided highly promising evidence that PVAT
inflammation plays a key role at various stages of CVD. One
powerful example of this is the recent work illuminating a role
for perivascular inflammation as an alteration that precedes
atherosclerotic plaque formation and even the development of
endothelial dysfunction and oxidative stress in ApoE−/− mice
(Skiba et al., 2017). Specifically, the authors found increased
leukocyte infiltration in the perivascular tissue when compared
to the vessel wall. Furthermore, it was demonstrated that PVAT
or adventitial inflammation and infiltration with macrophages
and T cells precede not only significant atherosclerotic
plaque development, but also the impairment of endothelium-
dependent NO bioavailability. In support of this finding, it was
previously shown that major risk factors for atherosclerosis,
including hypertension, hyperlipidemia or ty 2 diabetes promote
perivascular inflammation before and during development of
atherosclerosis (Galkina et al., 2006; Galkina and Ley, 2009; Sagan
et al., 2012; Guzik et al., 2013).
Molecular mechanisms linking PVAT inflammation in obesity
to CVD indicate several key components. These may include
chemotactic migration of PVAT immune cells into adventitia,
with release of cytokines, which can alter vascular function
(Mikolajczyk et al., 2016). In this regard, it was previously
demonstrated that human PVAT exhibits a strong chemotactic
activity on monocytes, granulocytes, and T lymphocytes that is
mainly mediated by the secretion of IL-8 and MCP-1, which
are known proatherogenic chemokines and their production is
increased in obesity. These mediators are likely to contribute
to the infiltration of leukocytes at the interface between PVAT
and adventitia of atherosclerotic aortas (Henrichot et al., 2005).
Visceral adipose tissue accumulation also promotes an increase
in the secretion of angiopoietin-like protein 2 (Angptl2), a pro-
inflammatory factor derived from adipocytes and considered
a key mediator of chronic adipose tissue inflammation and
obesity-related systemic insulin resistance (Tabata et al., 2009). In
fact, Angptl2 secreted by PVAT accelerates neointimal formation
after endovascular injury in mice by increasing inflammation-
related gene expression and by accelerating extracellular matrix
degradation (Tian et al., 2013). In line with these experimental
findings, the authors provided relevant clinical data that strongly
suggest that PVAT-secreted Angptl2 plays a significant role in
accelerating vascular inflammation by cooperating with pro-
inflammatory TNF-α or counteracting the anti-inflammatory
activity of adiponectin, potentially leading to development of
atherosclerosis in humans (Tian et al., 2013).
PVAT inflammation may also be associated with altered
release of adipokines and other adipocyte-derived relaxing
factors (Antonopoulos et al., 2015; Woodward et al., 2017).
Initial support for this understanding came from the findings
that perivascular adipocytes from human and mice without
atherosclerotic disease exhibit a heightened proinflammatory
state and reduced adipocytic differentiation under basal
conditions as compared with adipocytes derived from
subcutaneous and visceral adipose depots, and that high-
fat feeding causes further reductions in adipocyte-associated
gene expression while upregulates proinflammatory gene
expression (Chatterjee et al., 2009). Specifically, secretion of
the anti-inflammatory adipokine adiponectin is markedly
reduced, whereas that of proinflammatory cytokines IL-6, IL-8,
and MCP-1, is markedly increased in perivascular adipocytes.
These changes have also direct effects on the PVAT vasoactive
properties, as evidenced in animal and human small-artery
studies, where hypoxia and inflammation were shown to
attenuate the local vasoactive properties of PVAT by oxidative
stress (Greenstein et al., 2009).
In addition to the previously-mentioned adipokines,
chemerin, a secreted protein originally revealed as a
chemoattractant molecule for immature dendritic cells and
macrophages (Wittamer et al., 2003) is now considered a novel
adipokine that regulates adipogenesis, adipocyte metabolism
(Bozaoglu et al., 2007; Goralski et al., 2007) and inflammation
(Parolini et al., 2007; Cash et al., 2010). Chemerin acts through
CMKLR1 (chemokine-like receptor 1) or ChemR23 (chemerin
receptor 23), which is expressed in macrophages, dendritic cells,
adipocytes and vascular cells (Zabel et al., 2005, 2006; Parolini
et al., 2007). Chemerin is considered a biomarker for adiposity
since its plasma levels strongly associate with BMI and is linked
to obesity and metabolic syndrome, a cluster of metabolic
disorders that increase the risk for diabetes and CVD (Bozaoglu
et al., 2009; Li et al., 2014). Furthermore, serum chemerin levels
are significantly elevated in morbidly obese patients and reduced
with the weight loss after bariatric surgery. The strong decrease
of chemerin after surgery was associated with an improvement
in insulin sensitivity and blood glucose, which further support
the key role of this adipokine in mediating metabolic alterations
in obesity (Ress et al., 2010; Sell et al., 2010). Animal studies
reported the parallel findings that knockout mice for the
primary receptor for chemerin, ChemR23, exhibit reduced food
consumption, weight gain, and adiposity (Ernst et al., 2012).
Consistent with this phenotype, ChemR23 knockout mice also
displayed lower fasting blood glucose and serum insulin levels.
Recent observations have also shown that chemerin is
highly expressed in PVAT. Spiroglou et al. first detected
chemerin expression in epicardial and periaortic adipose tissue
and demonstrated a positive correlation of this adipokine
with both aortic and coronary atherosclerosis (Spiroglou
et al., 2010). Most recently, Watts and her co-workers
reported that chemerin produced by periaortic PVAT stimulates
vascular contraction through the receptor typically attributed
to function only in immune cells. Moreover, arteries from
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obese or hypertensive mice or obese humans with dysfunctional
endothelium demonstrated amplified contractions in response to
chemerin (Watts et al., 2013). Although there is no empirical
evidence linking specific chemerin signaling pathways with
the PVAT inflammation, a bulk of animal and human studies
exploring the immune functions of chemerin make this a
very plausible possibility. CMKLR1 is expressed in several
immune cell types known to accumulate in obese adipose tissue
(Wittamer et al., 2003; Parolini et al., 2007; Cash et al., 2010).
Sell and collaborators demonstrated that chemerin activates
the NF-κB pathway and impairs glucose uptake in skeletal
muscle cells (Sell et al., 2010). In human endothelial cells, it
was shown a significant upregulation of chemerin receptor by
pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6
(Kaur et al., 2010). Accordingly, circulating levels of chemerin
are elevated in diseases associated with chronic inflammation,
including obesity and the metabolic syndrome (Wittamer et al.,
2003; Bozaoglu et al., 2009; Li et al., 2014). Our recent studies
also point to a role of chemerin in regulating inflammatory
processes. Chemerin was shown to decrease NO-dependent
cGMP signaling, thereby reducing vascular relaxation in rat
aorta, an effect related to increased generation of O−2 , an
important mediator of inflammation (Neves et al., 2014).
In line with these findings, we demonstrated that chemerin,
through Nox activation and redox-sensitive MAPKs signaling,
exerts proapoptotic, proinflammatory, and proliferative effects in
human vascular cells (Neves et al., 2015).
Taken together, these findings not only provide multiple
layers of potential mediators for the inflammatory component of
PVAT in obesity but also clearly demonstrate that bidirectional
interactions between that the systemic metabolic inflammation
and local immune components are critical considerations
in determining the physiological and pathological vascular
outcomes associated with obesity. The proximity of PVAT
as a rich source of proinflammatory cytokines and other
mediators together with the associated alterations in this tissue
support the concept that specific changes of local adipose tissue
depots contribute to disease processes in the neighboring vessel
wall.
CLINICAL MEASURE OF PERIVASCULAR
ADIPOSE TISSUE IN
OBESITY-ASSOCIATED
CARDIOVASCULAR RISK ASSESSMENT:
FINDING THE POINT
Some of the initial thoughts and considerations of the reciprocal
relationship between PVAT and risk factors for CVD have
been provided by clinical findings showing an association
between both perivascular and epicardial adipose tissue with
the main anthropometric and clinical parameters of the
metabolic syndrome (Iacobellis et al., 2003b). In fact, a very
good correlation is observed between epicardial adipose tissue,
assessed by echocardiography, and waist circumference, diastolic
blood pressure, fasting plasma insulin, LDL cholesterol, and
plasma adiponectin (Iacobellis et al., 2003b). Importantly, the
association of insulin sensitivity and low adiponectin levels with
the epicardial fat thickness is independent of BMI, suggesting
that PVAT assessment might provide a more sensitive and
more specific measure of the true visceral fat content (Iacobellis
et al., 2003a). In support of these findings, a recent meta-
analysis of published reports concluded that echocardiographic
epicardial adipose thickness is significantly higher in patients
with metabolic syndrome than in those without it (Pierdomenico
et al., 2013).
Echocardiographic evaluation of epicardial adipose tissue
thickness is considered a very reliable method to measure visceral
adiposity, as first proposed and validated by Iacobellis et al.
(2005). It is also relatively cheap and easy to perform as a
screening test for assessment of patients suspected to be at
risk for cardiovascular or metabolic outcomes. However, the
technic provides only measurements of the regional thickness
of epicardial adipose tissue and presents the risk to confuse
pericardial fluid with adipose tissue since the fluid also shows up
as relatively echo-free on an echocardiograph (Singh et al., 2007).
The advances in imaging technology have enabled a more direct
quantitative assessment of the local fat depots and have also been
the basis for investigations into the possibility that PVAT acts
as direct modulator of metabolism and cardiovascular function.
From this perspective, clinical findings showed that volumetric
quantification of epicardial and peri-coronary adipose tissue
thickness by computed tomography, which provides a more
accurate assessment due to its higher spatial resolution, is also
positively related with parameters of obesity, such as BMI, waist
circumference and the abdominal visceral adipose tissue mass
(Gorter et al., 2008). In line with this, PVAT thickness, measured
by computed tomography in the areas of right coronary artery,
left anterior descending artery and left circumflex coronary
artery is positively associated with waist circumference, waist-to-
hip ratio, BMI, blood glucose, triglycerides, and systolic blood
pressure. Epicardial adipose tissue is also linked to coronary
calcification, a knownmarker of coronary atherosclerosis (de Vos
et al., 2008).
In agreement with the above observations, abdominal
periaortic adipose tissue and thoracic periaortic adipose tissue
volume, measured by computed tomography, are consistently
correlated with visceral abdominal fat, subcutaneous abdominal
fat, waist circumference, and BMI in a random subset of
participants from the Framingham Heart Study (Schlett et al.,
2009). Thanassoulis et al. extended these findings by showing that
both thoracic and abdominal periaortic adipose tissue volumes,
measured using the same approach, are associated with higher
aortic dimensions even after adjustment for other vascular and
metabolic risk factors including global measures of obesity such
as BMI (Thanassoulis et al., 2012). By contrast, the study of
Rosito et al. found no significant associations between pericardial
fat and CVD risk factors compared with visceral fat when both
were considered in the same model. Nevertheless, the authors
evidenced strong correlations between pericardial fat volume and
metabolic risk factors even after adjusting for many potential
confounders, including age, smoking, alcohol use, and physical
activity. Furthermore, pericardial fat was found to be associated
with coronary artery Ca2+ and abdominal aortic Ca2+ even after
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metabolic risk factors and visceral adipose tissue were accounted
for, which is consistent with the postulation that pericardial fat
may in fact exert a harmful perivascular effect on the coronary
arteries (Rosito et al., 2008).
SUMMARY
There is tremendous wealth in the mechanisms that support
the understanding of the relationship between excess adiposity
and cardiovascular risk. The strongest evidence comes from the
observations of basic science and translational studies regarding
important physiological process that occur in adipose tissue
and deleterious effects of relevant importance on vascular
complications. It is interesting to consider the role that
adipokines play among the mechanisms whereby adipocytes
influence vascular function. However, there is considerably more
work to be performed in both basic science and clinical areas
to understand and reduce the enhanced CVD risk that is
evident in the obese state. Clearly, these intriguing observations
are not sufficient to answer the question whether increased
PVAT mass represents a surrogate marker of cardiovascular
risk or an independent pathogenic variable. However, outcome
studies need to establish whether PVAT depots have prognostic
significance and may therefore provide additional evidence for
a causal relationship. Although the reduction of whole-body fat
would be ideal among individuals who have obesity, a thoughtful
consideration of the additional benefits of targeting fat depots at
specific locations in individuals at greater cardiometabolic risk
represents an alternative approach.
Further dissection of the vascular signaling pathways altered
by PVAT-derived factors will likely reveal functional strategies
for suppressing the negative effects of abnormal adipose tissue
excess on CVD complications without altering the beneficial
effects of normal fat depots. The challenges remaining in
this field can be identified in two different areas. How does
structural and functional changes of PVAT start in obesity
and at what point does it become detrimental? What are the
appropriate model systems and paths to elucidate the unknown
mechanisms to prevent or treat human CVD? Regarding
the contribution of new characterized adipokines, there are
also several interesting and emerging concepts. Given these
challenges, and the need for therapeutic approaches that do
not permanently interfere with entire physiological effects of
the PVAT, conveying the experimental insights into successful
clinical interventions will require collaborative and diverse
cross studies, new experimental approaches and integration
of genetic variations with other environmental modifiers to
establish links with complex cardiovascular phenotypes and
facilitate successful translation to human disease.
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